Onconic Therapeutics Secures Clinical Basis for Combining Zastaprazan With Cardiovascular Drugs
Onconic Therapeutics found no clinically meaningful drug interactions when combining its GERD drug Zastaprazan with four cardiovascular treatments, securing a basis for co-administration.
Read the full articleYou might also wanna read
STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug
AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive market for drug
Pfizer Aktie: FDA lässt PADCEV-Kombi zu
Die US-Gesundheitsbehörde FDA hat die Kombination aus PADCEV und Keytruda für die Behandlung von Patienten mit muskelinvasivem Blasenkrebs (
An Observational Study to Evaluate the Efficacy and Safety of K-CAB Tab./K-CAB ODT(Tegoprazan) in GERD Patients
Conditions : GERD (Gastroesophageal Reflux Disease) Sponsors : HK inno.N Corporation Recruiting
A Study of Combination Therapy in Patients With Resectable Liver Cancer
Conditions : Liver Cancer (Primary and Metastatic) Interventions : Drug: Hepatic Arterial Infusion Chemotherapy Combined with Adebrelimab Pl
Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer
Conditions : Castration-Resistant Prostate Cancer (CRPC) Interventions : Drug: CP-PCA07; Drug: Enzalutamide 40 mg capsule Sponsors : Hyundai
Tucatinib Plus Trastuzumab Deruxtecan Shows Activity but No Clear Added Benefit in HER2+ Advanced Breast Cancer
A phase 2 study published in Clinical Breast Cancer evaluated whether combining tucatinib with trastuzumab deruxtecan could improve outcomes
Comments
Sign in to join the conversation.
No comments yet. Be the first.